Drug: Bevacizumab Injury: Disease progression Quarter: 2016Q3
Total Records: 58 Number of Pages: 3
| Event ID | DRUGNAME | PT | Drug Manufacturer | Patient Age | Sex | Weight | Date (YYYYMMDD) | Country |
|---|---|---|---|---|---|---|---|---|
| 104219112 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160825 | IT | |
| 109048002 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160819 | FR | |
| 120387423 | Bevacizumab | Disease progression | ROCHE | 56.00 YR | F | 0 | 20160726 | NL |
| 124325432 | Bevacizumab | Disease progression | RANBAXY | 50.00 YR | F | 0 | 20160715 | JP |
| 125245191 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160704 | US | |
| 125245201 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160704 | US | |
| 125245211 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160704 | US | |
| 125245271 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160704 | US | |
| 125268171 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160705 | US | |
| 125268391 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160705 | US | |
| 125268431 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160705 | US | |
| 125268481 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160705 | US | |
| 125295251 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160706 | US | |
| 125296521 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160706 | US | |
| 125296771 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160706 | US | |
| 125297101 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160706 | US | |
| 125297161 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160706 | US | |
| 125297181 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160706 | US | |
| 125299131 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160706 | US | |
| 125299161 | Bevacizumab | Disease progression | CIPLA | 0.00 | 0 | 20160706 | US |
Total Records: 58 Number of Pages: 3